pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

821 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Biopharma pay report: Top-paid CSOs, CMOs of 2025
    Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…
    Endpoints · 1mo ago↗ source
  • Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
    Parabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...
    Endpoints · 1mo ago↗ source
  • Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
    Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib indu…
← prev
page 14 of 33
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • Neion Bio raises $23M Series A to make proteins from chicken eggs
    Neion Bio has secured an oversubscribed $23 million Series A to further develop its technology that uses chicken eggs to make active pharmaceutical ingredients for biologic drugs. The funding rou…
    Endpoints · 1mo ago↗ source
  • Exclusive: Genentech closes infectious disease unit in wave of research layoffs
    Roche's Genentech underwent another round of layoffs this week in its early research and development group, Endpoints News has learned, which included shuttering two research units and the departur…
    Endpoints · 1mo ago↗ source
  • Rare disease biotech Beren adds $300M from new financings
    Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug. The biotech announced Wednesday that it raised $135 ...
    Endpoints · 1mo ago↗ source
  • Parabilis CEO Mathai Mammen on biotech's record IPO
    Parabilis Medicines cemented the largest biotech IPO in industry history on Wednesday with its $670 million debut on the Nasdaq. But the Cambridge, MA-based drug developer won't be celebrating at…
    Endpoints · 1mo ago↗ source
  • Novartis and Orionis strike second molecular glue deal for $40M upfront
    Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones. The Boston and Belgian biotech will ...
    Endpoints · 1mo ago↗ source
  • SonoThera raises $125M for non-viral gene therapy approach
    SonoThera has secured $125 million to take its ultrasound-based gene therapy technology into the clinic. The company is focused on two lead programs in Duchenne muscular dystrophy and autosomal d…
    Endpoints · 1mo ago↗ source
  • Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation
    Shattuck Labs initiates $75M public offering: The US biotech {$STTK} is selling over 10.5 million shares for $4 apiece, and issuing pre-funded warrants for certain investors. The offering is set to…
    Endpoints · 1mo ago↗ source
  • Biotech pay analysis: 12 execs with $35M+ M&A golden parachutes
    A dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found. The drug industry is undergoing a historic stretch of…
    Endpoints · 1mo ago↗ source
  • Ethyreal lands $101M to treat both Graves' and thyroid eye disease
    A biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves' disease and thyroid eye disease, and the startup plans to enter the…
    Endpoints · 1mo ago↗ source
  • Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
    Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of…
    Endpoints · 1mo ago↗ source
  • Parabilis' $670M IPO sets new biotech record, will fund cancer drug
    Despite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever s…
    Endpoints · 1mo ago↗ source
  • Eli Lilly's claims data deadline may kick off new 340B fight
    Eli Lilly’s deadline has passed for hospitals to comply with its new 340B claims data policy, and for now the pharma company is staying mum on its next steps. But just because Lilly is declining ...
    Endpoints · 1mo ago↗ source
  • Grace Science says FDA bottleneck jeopardizes rare disease therapy
    Grace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line. Co-founded by Nobel laureate Carolyn Bertozzi…
    Endpoints · 1mo ago↗ source
  • A different approach to lowering healthcare costs
    Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...
    Endpoints · 1mo ago↗ source
  • How K Health moved AI chatbots into hospitals
    Startups that fashion themselves as AI doctors that patients can chat with have gained traction over the last year. One of these startups, K Health, began in 2016 as a symptom checker ...
    Endpoints · 1mo ago↗ source
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…
    Endpoints · 1mo ago↗ source
  • Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
    Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…
    Endpoints · 1mo ago↗ source
  • Endpoints Women in Biopharma: Nominate for 2026
    Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…
    Endpoints · 1mo ago↗ source
  • Pharma and biotech salaries: Top-paying companies of 2025
    The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…
    Endpoints · 1mo ago↗ source
  • Post-Hoc Live: How much is everyone in biopharma getting paid?
    The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the in…
    Endpoints · 1mo ago↗ source
  • WuXi AppTec added to Pentagon's list of companies linked to Chinese military
    Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...
    Endpoints · 1mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugm…
    Endpoints · 1mo ago↗ source